Health Care Equipment

Zynex

SEC Ends Investigation of Zynex Without Enforcement Action

Zynex Inc. Secures $22.3 Million Debtor-in-Possession Loan

US Pre-market Zynex and ZIM Stock Price Anomaly

Zynex Inc. Obtains $22.3 Million in DIP Financing

Zynex Inc Secures $22.3 Million in Temporary Financing Facility

Zynex released FY2025 9 Months Earnings on November 17 Pre-Market EST, with actual revenue of USD 62.23 M and EPS of USD -2.412

Zynex released FY2025 Q3 earnings on November 17 Pre-Market (EST), actual revenue USD 13.36 M (forecast USD 24.53 M), actual EPS USD -1.42 (forecast USD -0.16)

Zynex to Release FY2025 Q3 Earnings on November 18 Pre-Market EST, Forecast Revenue USD 24.53 M, EPS USD -0.16

Zynex released FY2025 Q2 earnings on July 31 After-Market EST, actual revenue USD 0 (forecast USD 27.38 M), actual EPS USD 0 (forecast USD -0.1966)

Zynex released FY2025 Semi-Annual earnings on July 31 After-Market EST, with actual revenue of USD 48.87 M and EPS of USD -0.9838

Zynex to release FY2025 Q2 earnings on July 31 After-Market EST, forecast revenue USD 27.38 M, EPS USD -0.1966

Zynex, Inc. Sued by Shareholders for Misleading Statements

ZYNEX Announces Steven Dyson as New CEO

Zynex, Inc. wins award in UK

Zynex Inc. Obtains Patent for Sepsis Detection Device

Zynex Inc Sees $5 Million in Annual Cost Savings from Layoffs

Deadline Approaching for Zynex, Inc. Class Action Suit

Zynex, Inc. Submits Important Document

Zynex investors urged to contact lawyer for potential losses

RBC Maintains Zynex Rating, Cuts Price Target

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

ZYXI

ZYXIQ

Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. and reminds investors of the April 21, 2026 deadline to seek lead plaintiff status in a federal securities class action. The firm alleges that Zynex made misleading statements regarding its revenue and compliance with industry regulations, leading to significant stock price declines. Investors who suffered losses between February 25, 2021, and December 15, 2025, are encouraged to contact the firm for legal options.

prnewswire

ZYNEX INC

09:18 ETZYXIQ INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Zynex Investors of Securities Class Action Deadline on April 21, 2026

Hagens Berman has filed a securities class action lawsuit against Zynex, Inc. following its bankruptcy and allegations of a fraudulent overbilling scheme. The lawsuit claims Zynex engaged in excessive medical supply shipments to inflate billings, leading to a significant loss for investors. The firm urges affected investors to submit their losses by April 21, 2026, to be considered for lead plaintiff status. The case highlights serious allegations against former executives, including health care and securities fraud, resulting in Zynex's delisting from Nasdaq.

14:26 ETZYXI SHAREHOLDER ALERT: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

Hagens Berman has filed a securities class action lawsuit against Zynex, Inc. following its bankruptcy and allegations of a fraudulent overbilling scheme. The lawsuit claims Zynex engaged in excessive medical supply shipments to inflate billings, leading to a suspension of payments from its largest payor, Tricare. Former executives face criminal charges, and Zynex's practices resulted in significant losses for investors. A critical deadline for investors to act as Lead Plaintiff is April 21, 2026.

16:45 ETZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

Hagens Berman has filed a securities class action lawsuit against Zynex, Inc. following its bankruptcy and allegations of a systematic overbilling scheme. The lawsuit claims Zynex engaged in excessive shipping of medical supplies to inflate billings, leading to a suspension of payments from its largest payor, Tricare. The firm is urging investors who suffered losses during the class period (February 25, 2021 - December 15, 2025) to submit their claims by April 21, 2026. Former executives face criminal charges for fraud.

12:31 ETZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

14:05 ETHagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements

Hagens Berman has filed a securities class action lawsuit against former Zynex executives, alleging they misled investors about the company's growth through fraudulent billing practices. The lawsuit seeks to recover losses for investors who purchased Zynex securities between February 25, 2021, and December 15, 2025. Key allegations include systemic overbilling and a significant forfeiture to the Tricare military health program. Investors have until April 21, 2026, to apply as Lead Plaintiff in the case.

17:03 ETZynex Investor Alert: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

Taiwanese companies SURGLASSES, Imedtac, Wincomm, and Zinexts showcased AI healthcare solutions at HIMSS 2026, marking Taiwan Excellence's debut at the event. The pavilion highlighted deployment-ready technologies aimed at enhancing clinical workflows and care delivery. The event, organized by TAITRA, emphasized U.S.-Taiwan healthcare collaboration, with over 25,000 attendees expected. VIP guests symbolically activated the pavilion, underscoring a commitment to human-centered, AI-enabled healthcare. Eleven Taiwanese brands will demonstrate innovations in Smart Healthcare, AI Applications, and Medical Technology throughout the conference.

MorningStar

VanEck Biotech ETF

VG Health

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

HIMSS 2026: Taiwanese Innovators Showcase Deployment-Ready AI Healthcare Solutions

Faruqi & Faruqi, LLP is reminding Zynex, Inc. investors of the April 21, 2026 deadline to seek lead plaintiff status in a federal securities class action. The firm is investigating claims that Zynex made misleading statements regarding its revenue and compliance with industry regulations, leading to significant stock price declines. Investors who suffered losses between February 25, 2021, and December 15, 2025, are encouraged to contact the firm for legal options. The class action alleges fraudulent overbilling practices and scrutiny from insurers, including Tricare, Zynex's largest customer.

09:14 ETZYXIQ CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Zynex Investors of Securities Class Action Deadline on April 21, 2026

Zynex(ZYXI.US)